These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37827257)

  • 21. Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy.
    Espinola CW; Khoo Y; Parmar R; Demchenko I; Frey BN; Milev RV; Ravindran AV; Parikh SV; Ho K; Rotzinger S; Lou W; Lam RW; Kennedy SH; Bhat V;
    Brain Behav; 2022 May; 12(5):e2555. PubMed ID: 35333448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report.
    Morton E; Bhat V; Giacobbe P; Lou W; Michalak EE; McInerney S; Chakrabarty T; Frey BN; Milev RV; Müller DJ; Parikh SV; Rotzinger S; Kennedy SH; Lam RW;
    CNS Drugs; 2021 Apr; 35(4):439-450. PubMed ID: 33860922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sexual function improves as depressive symptoms decrease during treatment with escitalopram: results of a naturalistic study of patients with major depressive disorder.
    Weber S; Frokjaer VG; Armand S; Nielsen JH; Knudsen GM; Joergensen MB; Stenbaek DS; Giraldi A
    J Sex Med; 2023 Feb; 20(2):161-169. PubMed ID: 36763929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
    Baldwin DS; Cooper JA; Huusom AK; Hindmarch I
    Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
    Vieta E; Sluth LB; Olsen CK
    J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.
    Lepola U; Wade A; Andersen HF
    Int Clin Psychopharmacol; 2004 May; 19(3):149-55. PubMed ID: 15107657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of solution focused group therapy on depressive symptoms and cognitive flexibility of depressive disorder patient.
    Duan D; Wang W; Zhang J; Gu Z
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Sept 28; 48(9):1343-1349. PubMed ID: 38044645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study.
    Han C; Wang SM; Kwak KP; Won WY; Lee H; Chang CM; Tang TC; Pae CU
    J Psychiatr Res; 2015; 66-67():84-94. PubMed ID: 26013203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence.
    Han DH; Kim SM; Choi JE; Min KJ; Renshaw PF
    J Psychopharmacol; 2013 Mar; 27(3):282-91. PubMed ID: 23325372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
    Udristoiu T; Dehelean P; Nuss P; Raba V; Picarel-Blanchot F; de Bodinat C
    J Affect Disord; 2016 Jul; 199():6-12. PubMed ID: 27054610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: Results from a randomized, double-blind, non-inferiority trial.
    Shen Y; Zhao Q; Yu Y; Tan Y; Zhang H; Xu X; Wang Z; Li Y; Hu J; Zhong J; Li H
    J Affect Disord; 2019 Oct; 257():143-149. PubMed ID: 31301615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of escitalopram in treatment of severe depression in Chinese population.
    Si T; Wang G; Yang F; Fang Y; Fang M; Li J; Dong J; Shen X; Zhuo J; Rui Q; Wang J; Cuili H
    Metab Brain Dis; 2017 Jun; 32(3):891-901. PubMed ID: 28299626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baseline severity of depression predicts antidepressant drug response relative to escitalopram.
    Kilts CD; Wade AG; Andersen HF; Schlaepfer TE
    Expert Opin Pharmacother; 2009 Apr; 10(6):927-36. PubMed ID: 19317630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.
    Wisniewski SR; Chen CC; Kim E; Kan HJ; Guo Z; Carlson BX; Tran QV; Pikalov A
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):965-72. PubMed ID: 19662630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: a 12-week, open-label prospective trial.
    Park HY; Lee BJ; Kim JH; Bae JN; Hahm BJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):318-23. PubMed ID: 22142651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
    Waugh J; Goa KL
    CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.